This content is in French.
Cardiovascular and renal benefits of empagliflozin and GLP-1 analogues
14 février 2024
The aim of this American study was to compare the renal and cardiac efficacy of empagliflozin and cardioprotective GLP-1 analogues in patients at high cardiovascular risk. A total of 141,541 matched pairs were…
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
: Phyo T Htoo et al. Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study. Cardiovasc Diabetol. 2024 Feb 8;23(1):57.
View the sourceOther recent articles
Beyond BMI: The Hidden Risks of Normal-Weight Obesity in Women
22 octobre 2026
The Emerging Role of Exercise in Triple-Negative Breast Cancer
22 octobre 2026
Artificial Intelligence in Triple-Negative Breast Cancer: Global Progress and Perspectives
21 octobre 2026